144 related articles for article (PubMed ID: 20202054)
21. WT1 expression levels at diagnosis could predict long-term time-to-progression in adult patients affected by acute myeloid leukaemia and myelodysplastic syndromes.
Galimberti S; Ghio F; Guerrini F; Ciabatti E; Grassi S; Ferreri MI; Petrini M
Br J Haematol; 2010 May; 149(3):451-4. PubMed ID: 20085581
[No Abstract] [Full Text] [Related]
22. [Re-evaluation of classification of myelodysplastic syndromes with low percentage bone marrow blasts].
Yu MH; Xu ZF; Li L; Nie L; Liu L; Zhang Y; Qin TJ; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):3-7. PubMed ID: 19563026
[TBL] [Abstract][Full Text] [Related]
23. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS.
Park MJ; Kim HJ; Kim SH; Kim DH; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW
Eur J Haematol; 2008 Nov; 81(5):364-73. PubMed ID: 18637029
[TBL] [Abstract][Full Text] [Related]
24. Outcome of patients with myelodysplastic syndromes: experience from a single institution in South Australia.
Hui CH; Horvath N; Lewis I; To LB; Szabo F
Intern Med J; 2008 Nov; 38(11):824-8. PubMed ID: 18284457
[TBL] [Abstract][Full Text] [Related]
25. Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation.
Lim ZY; Fiaccadori V; Gandhi S; Hayden J; Kenyon M; Ireland R; Marsh J; Ho AY; Mufti GJ; Pagliuca A
Leuk Res; 2010 Jun; 34(6):723-7. PubMed ID: 19944463
[TBL] [Abstract][Full Text] [Related]
26. [Study on the immunophenotype of myeloid cells in myelodysplastic syndromes and its clinical implications].
Shao Z; Chen G; Lin Z; Zhang Y; Hao Y; Chu Y; Qian L; Yang T; Yang C; Feng B
Zhonghua Xue Ye Xue Za Zhi; 1997 Feb; 18(2):80-3. PubMed ID: 15622783
[TBL] [Abstract][Full Text] [Related]
27. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.
Hu Q; Dey AL; Yang Y; Shen Y; Jilani IB; Estey EH; Kantarjian HM; Giles FJ; Albitar M
Cancer; 2004 May; 100(9):1884-91. PubMed ID: 15112269
[TBL] [Abstract][Full Text] [Related]
28. [An analysis of prognostic factors in 80 myelodysplastic syndrome].
Xu XQ; Wang JM; Lu SQ; Chen L; Yang JM; Zhang WP; Song XM; Xu YQ; Gong SL; Hou J; Ni X
Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):723-7. PubMed ID: 19176004
[TBL] [Abstract][Full Text] [Related]
29. [Expression of differentiation antigens on bone marrow myeloid cells of the patients with myelodysplastic syndromes and its clinical significances].
Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH
Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(10):672-7. PubMed ID: 20450725
[TBL] [Abstract][Full Text] [Related]
30. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
Kao JM; McMillan A; Greenberg PL
Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
[TBL] [Abstract][Full Text] [Related]
31. FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia.
Pinheiro RF; de Sá Moreira E; Silva MR; Alberto FL; Chauffaille Mde L
Cancer Genet Cytogenet; 2008 Jun; 183(2):89-93. PubMed ID: 18503825
[TBL] [Abstract][Full Text] [Related]
32. Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis?
Sieglová Z; Zilovcová S; Cermák J; Ríhová H; Brezinová D; Dvoráková R; Marková M; Maaloufová J; Sajdová J; Brezinová J; Zemanová Z; Michalová K
Leuk Res; 2004 Oct; 28(10):1013-21. PubMed ID: 15289012
[TBL] [Abstract][Full Text] [Related]
33. Clinical prognostic factors and outcomes of essential thrombocythemia when transformed to myelodysplastic syndromes and acute myeloid leukemia.
Suleiman Y; Dalia S; Liu JJ; Bowers JW; Padron E; Lancet JE; Fulp W; Moscinski LC; Komrokji RS; Zuckerman KS; Zhang L
Leuk Res; 2016 Mar; 42():52-8. PubMed ID: 26894965
[TBL] [Abstract][Full Text] [Related]
34. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA
Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372
[TBL] [Abstract][Full Text] [Related]
35. Cutaneous leukaemic infiltrations in a patient with previously undiagnosed myelodysplastic syndrome.
Schneider LA; Weber L; Viardot A; Schubert R; Hinrichs R; Scharffetter-Kochanek K
Clin Exp Dermatol; 2004 Sep; 29(5):468-70. PubMed ID: 15347325
[TBL] [Abstract][Full Text] [Related]
36. Telomerase activity in myelodysplastic syndromes.
Gürkan E; Tanriverdi K; Başlamişli F
Leuk Res; 2005 Oct; 29(10):1131-9. PubMed ID: 16111531
[TBL] [Abstract][Full Text] [Related]
37. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.
Shih LY; Lin TL; Wang PN; Wu JH; Dunn P; Kuo MC; Huang CF
Cancer; 2004 Sep; 101(5):989-98. PubMed ID: 15329908
[TBL] [Abstract][Full Text] [Related]
38. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
[TBL] [Abstract][Full Text] [Related]
39. Bone marrow leukaemic transformation of myelodysplastic syndrome revealed by a cutaneous Langerhans cell infiltrate: partial response to azacitidine.
Osio A; Elfatoiki F; Raffoux E; Vignon-Pennamen MD; de Labarthe A; Cordoliani F; Petrella T; Bagot M; Janin A; Battistella M; Bouaziz JD
Eur J Dermatol; 2013; 23(5):710-1. PubMed ID: 24125873
[No Abstract] [Full Text] [Related]
40. [Extramedullary initial manifestations of acute myeloid leukemia (AML)].
Schmitt-Gräff A; Wickenhauser C; Kvasnicka HM; Dries V; Thiele J
Pathologe; 2002 Nov; 23(6):397-404. PubMed ID: 12436291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
